1. Pink Sheet
  2. >>Market Access

Digital Age: Otsuka Sets Sights On Abilify Combo Tablet With Sensor

 
• By Jessica Merrill

First-of-its-kind NDA is for a combination product of Abilify embedded with an ingestible sensor to measure adherence and physiologic response. Otsuka sees opportunities to extend brand facing generic competition and for combo approach with future medicines too.

Otsuka Pharmaceutical Co. Ltd. has set its sights on a new digital tablet of Abilify (aripiprazole) to extend the life of the brand that is now facing generic competition. The company announced Sept. 10 that a combination of the atypical antipsychotic embedded with an ingestible sensor developed by partner Proteus Digital Health Inc. has been accepted for filing by FDA. The PDUFA date is in April 2016.

The combination represents the first time such a pill has been submitted to FDA for review, according to the company

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

What The EMA Can Teach HTA Bodies About Joint Clinical Assessments

 
• By Francesca Bruce

EU-level joint clinical assessments conducted under the Health Technology Assessment Regulation need to be more flexible when it comes to evidence requirements, according to experts speaking at a gene and cell therapy conference.

Moderna Pivots To Increase Focus On Cancer Amid US Vaccine Policy Changes

 
• By Joseph Haas

During its first quarter earnings call, Moderna avoided criticizing vaccine policy changes, but de-emphasized its flu/COVID-19 vaccine for those under age 50 and prioritized cancer programs.

What MAHA Means For US FDA: Prevention Is Not What You Think

 
• By Michael McCaughan

US HHS Advisor Calley Means said new pathways for root-cause treatments are part of the HHS Secretary Robert F. Kennedy Jr.’s vision for the FDA. But what most biopharma companies consider preventative medicines are not what he has in mind, nor does he seem to see those companies as part of the solution.